BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Cessation
Intimation of Cessation as per Regulation 30 of LODR Regulations.15-05-2023
15-05-2023
BAL PHARMA LTD. - 524824 - Non Applicability Of Filing Statement Of Deviation & Variation
We would like to clarify that as the Company has neither raised any funds through public issue, rights issue, preferential issue, QIP etc nor has any proceeds of the earlier issues outstanding for utilization for the quarter ended 31.03.2023, filing of statement of deviation/variation in utilization of funds raised is not applicable to the Company, for the above said quarter.11-05-2023
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Credit Rating
Acuite Rating & Research vide their credit rating rational issued on 24.04.2023 has assigned and reaffirmed the credit ratings of the Company, which is as follows. 01 Long Term Fund based facilities- ACUITE BBB- stable- Reaffirmed 02 Short term Non fund based facilities- ACUITE A3- Reaffirmed 03 Long term-Term Loan- ACUITE BBB- stable- Reaffirmed Rating rational issued by the credit rating agency is enclosed with this communication.25-04-2023
BAL PHARMA LTD. - 524824 - Statement As Per Regulation 32(1) Of LODR Regulation
We request you to kindly note that the proceeds of the preferential issue was utilized in cognizance with the objectives stated in the explanatory statement to the notice issued and the proceeds of the preferential issue is fully utilized as and when received by the Company. This is due to which the Company has not filed the statement of deviation/variation for the quarter ended 31.12.2022, in compliance with Regulation 32(1) of SEBI(LODR) Regulations,201520-04-2023
BAL PHARMA LTD. - 524824 - Regulation 7(3) Of SEBI(LODR) Regulations.
We are submitting to the exchange confirmation as prescribed under regulation 7(3) of SEBI (LODR) regulations, for the financial year ended 31.03.2023.18-04-2023
BAL PHARMA LTD. - 524824 - Compliance As Per Regulation 40(10) Of SEBI(LODR) Regulations,2015.
We are submitting to the exchange certificate from the practicing company secretary certifying compliance with Regulation 40(9) of SEBI(LODR) Regulations, for the financial year ended 31.03.202312-04-2023
BAL PHARMA LTD. - 524824 - Disclosure-Large Corporate
Sub : Non applicability of provisions of Large Corporate. Ref : SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018 144 dated November 26, 2018 read with amendments vide notifications dated August 10, 2021 and April 13, 2022. With reference to the above cited subject and reference , we would like to confirm that for the financial year ended March 31, 2023, Bal Pharma Limited ('the Company') is not a large corporate as the criteria notified by the above referred circulars for large corporates are not applicable to the Company.04-04-2023
BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate's received from our R&T agents i.e TSR Darashaw Pvt Ltd, we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 31.03.2023 have been furnished to all the stock exchanges where the equity shares of the Company are listed, within the prescribed time limit. The Share certificates received for dematerialization, if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner, within 15 days of the receipt of the certificate of security.03-04-2023
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading ) Regulations , 2015 , We wish to inform the exchanges that the trading window for dealing with the securities of the Company on the designated employees and their relatives will be closed from 1st April 2023 and up to 48 hours of the declaration of the audited financial results of the Company for the quarter and financial year ended 31/03/2023. The date of the Board meeting for declaration of the audited financial results, will be intimated to the exchanges in due course.29-03-2023
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agents i.e TSR Consultants Pvt Ltd, Mumbai, regarding notice for loss of share certificates by one of our shareholder23-02-2023